Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030

The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.

This in-site reader presents the headline and limited excerpt supplied through the publisher’s feed. The original reporting remains with MarketWatch.